Applying methylation haplotype analysis to cell-free DNA

DNA methylation has once been called the '5th DNA base' due to its importance in gene regulation, and has been studied for decades. With the advent of next-generation sequencing (NGS) methylation has been studied on a genome-wide level, an expensive process requiring both generating sequence data and analyzing sequence data many orders of magnitude higher than what a typical clinical laboratory can handle.

Targeted methylation approaches have historically not been developed due to technical hurdles. Singlera announces a unique approach, examining methylation haplotypes (adjacent methylation sites on the same contiguous strand of DNA) from cell-free DNA as a method for cancer biomarker detection.

By using a highly specific and targeted methylation enrichment method, both the overall sample input requirement is lowered and the overall amount of sequencing necessary for excellent sensitivity is reduced.

  • Empirical Classifier – Derived from over 20,000 methylation haplotypes and 10 years of volunteer samples

  • High Sensitivity and Specificity – Pilot study results show greater than 97% sensitivity and over 99% specificity *

  • Early Detection of Cancer – Data suggests detection of cancer four years before earliest conventional diagnosis

Efficient biomarker screening technology coupled with fast custom targeted methylation haplotyping and proprietary bioinformatics analysis.

Research

Take a closer look at our leading-edge research in methylation and its role in disease in top research publications.

Method

Learn how Singlera’s methylation haplotyping technology can give better cancer biomarker sensitivity.

Collaboration and Co-Development

Do you see promise in our methylation haplotype approach? Do you think it could complement work you are doing in developing in-vitro diagnostics for cancer?

Research Study Results

62%

Sensitivity of PanSeer 4 years pre-conventional diagnosis

92%

Specificity of PanSeer across 498 healthy individuals

97%

Sensitivity of ColonES in Stage I Colorectal cancer

99%

Specificity of ColonES in healthy individuals

 

0
Taizhou China volunteers
0
Years volunteers monitored
0
Number of methylation haplotype markers used in ColonES
0
Hours from DNA to sequencer-ready library

 

The Co-Founders of Singlera Genomics

Yuan Gao, CEO and Co-Founder of Singlera Genomics
Dr. Yuan Gao Ph.D., Chairman and Co-Founder
Dr. Kun Zhang Co-Founder Singlera Genomics
Kun Zhang, Ph.D., Co-founder and Scientific Advisor
Johny Zhang MBA
Johny Zhang, M.B.A., Co-Founder, Chief Executive Officer
Dr. Rui Liu CTO Singlera Genomics
Rui Liu, Ph.D., Co-Founder, Chief Technology Officer
Qiang Liu MBA
Qiang Liu, M.B.A., Co-Founder, Chief Operating Officer

Discover The Future

At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future.

Contact Us
Email Signup